

POSITIONING AND MARKET POTENTIAL OF CMS-024 (YSL, TYROSERLEUTIDE) IN HEPATIC CACNER IN CHINA

<https://marketpublishers.com/r/PC757D34AF1EN.html>

Date: October 2011

Pages: 2

Price: US\$ 500.00 (Single User License)

ID: PC757D34AF1EN

Abstracts

The report is a comprehensive analysis of the competitive landscape of Hepatic cancer drugs under development in China with an objective to figure out the market potential and positioning of China Medical System's lead drug candidate – CMS-024 (Tyroselerleutide, PhIII). China is the most important market for Hepatic cancer drugs as more than half of worldwide incidence of hepatic cancer occur in China.

CMS-024 is targeted in the early stage setting as an adjuvant treatment, where surgery and local ablation are the first line treatment options. Surgery is associated with a very high recurrence rate (35-65% within 5 years), and hence a number of drugs are being developed to address this potential unmet need. This 21 page presentation will provide a complete clinical profile of CMS-024, positioning of this tripeptide in current treatment paradigm of HCC in China, CMS-024 clinical profile vis-à-vis competition in adjuvant HCC setting and in the unresectable HCC setting and the market potential of CMS-024.

Contents

1. EXECUTIVE SUMMARY

2. DRUG OVERVIEW- CMS-024/YSL/TYROSERLEUTIDE

3. CMS-024 – MECHANISTIC EVIDENCE OF ROLE IN HEPATIC CANCER

4. REGULATORY AND CLINICAL DEVELOPMENT OF CMS-024- CHRONOLOGY OF EVENTS

5. CMS-024 –KEY FINDINGS FROM PRECLINICAL DATA

6. CMS-024- RESULTS OF REPORTED PH/II CLINICAL STUDY AND KEY CONCLUSION FROM THE RESULTS

7. PH III CLINICAL TRIAL DESIGN OF CMS-024 IN DETAIL - DO RECENT CHANGES IN TRIAL DESIGN POST DISCUSSION WITH SFDA ARE POSITIVE OR NEGATIVE?

Post surgical adjuvant setting- A better target than unresectable HCC or not?

8. PIPELINE DRUGS IN DEVELOPMENT IN ADJUVANT SETTING POST SURGERY IN HCC

Iodine I 131 ethiodized oil

Low dose thalidomide

Thymopentin

Nexavar

Cytokine induced killer cell

PI-88

9. CMS-024, HOW IT STANDS AGAINST NEXAVAR IN UNRESECTABLE HCC?

Clinical data comparison of Tyrosarleutide vs. Nexavar in Asian patient pool

Clinical data comparison of late stage pipeline drugs in treatment of HCC

a) Sutent (PFE)

b) Brivanib (BMY)

c) ABT-869 (ABT)

10. HEPATIC CANER- POTENTIAL MARKET IN CHINA

11. CONCLUSION:

CMS- 024 fits where in Current treatment Paradigm for treatment of HCC?

Surgery vs. local ablation therapy for treatment of early stage HCC? - How it will impact to potential of CMS-024?

Sales estimates and launch timeline of CMS-024 in China market

Approval and pricing

ANNEXURE

About CMS

Patent of CMS-024

Preclinical studies and important scientific publications

I would like to order

Product name: POSITIONING AND MARKET POTENTIAL OF CMS-024 (YSL, TYROSERLEUTIDE) IN HEPATIC CACNER IN CHINA

Product link: <https://marketpublishers.com/r/PC757D34AF1EN.html>

Price: US\$ 500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PC757D34AF1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

